Amidst revenue decline and significant cash burn, Durect Corp reports promising clinical trial results and strategic FDA interactions.
Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?